The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An ongoing phase 1–2a study of EO1001, an oral brain-penetrant pan-ErbB inhibitor, in patients with advanced ErbB-driven solid tumors including CNS disease.
 
Neil Sankar
Leadership - Edison Oncology
Stock and Other Ownership Interests - Edison Oncology
Consulting or Advisory Role - Edison Oncology
 
Jeffrey Bacha
Employment - Edison Oncology
Leadership - Edison Oncology; Rakovina Therapeutics
Stock and Other Ownership Interests - Edison Oncology; Rakovina Therapeutics
Consulting or Advisory Role - Sera BioPharma
Patents, Royalties, Other Intellectual Property - Edison Oncology
 
Sophia Frentzas
Leadership - CANCER TRIALS AUSTRALIA
Consulting or Advisory Role - AstraZeneca; GOG Foundation; MSD Oncology
Speakers' Bureau - MSD
Research Funding - Akeso Biopharma (Inst); Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); BeiGene (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Edison Oncology (Inst); Haihe Pharmaceutical (Inst); MSD Oncology (Inst); Takeda (Inst); Vivace Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DynamiCure Biotechnology
 
Malaka Ameratunga
No Relationships to Disclose
 
Amy Body
Research Funding - Akeso Biopharma (Inst); BeiGene (Inst); Day One Therapeutics (Inst); Domain Therapeutics (Inst); Gilead Sciences (Inst); Hanmi (Inst); Innovent Biologics (Inst); PMV Pharma (Inst); Prelude Therapeutics (Inst); Prestige BioPharma (Inst); Stingray Therapeutics (Inst); Vivace Therapeutics (Inst); Wellmarker Bio (Inst)
(OPTIONAL) Uncompensated Relationships - Hanmi
 
Daphne Day
No Relationships to Disclose
 
Richard Kelly
No Relationships to Disclose
 
Jeremy Neeman
No Relationships to Disclose
 
Sarath Kanekal
Consulting or Advisory Role - Edison Oncology
 
Ian Nisbet
Employment - Cartherics; Senz Oncology
Leadership - Cartherics; Senz Oncology
Stock and Other Ownership Interests - Cartherics
Speakers' Bureau - Edison Oncology
 
Kathy Skoff
Consulting or Advisory Role - Cartherics; Senz Oncology
 
Dennis Brown
Leadership - Edison Oncology; Valent Technologies
Stock and Other Ownership Interests - Edison Oncology; Valent Technologies
Consulting or Advisory Role - Rakovina Therapeutics
Patents, Royalties, Other Intellectual Property - Edison Oncology